Herceptin trastuzumab: Phase II; Marketed as first line therapy in combination with paclitaxel and as a single agent in second and third line therapy

Of 114 women with previously untreated HER2-positive metastatic breast

Read the full 93 word article

How to gain access

Continue reading with a
two-week free trial.